# Paclitaxel mIcelle Later-line cOmbined immunoTherapy for Biliary Tract Cancer

> **NCT07159204** · PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Biliary Tract Cancer (BTC)

## Interventions

- **DRUG:** Paclitaxel polymer micelle immunocombination

## Key facts

- **NCT ID:** NCT07159204
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-07-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07159204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07159204, "Paclitaxel mIcelle Later-line cOmbined immunoTherapy for Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07159204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*